Finance entity
Coverage clusters in markets, which accounts for 3 of those 4, with the remainder spread across 1 other category. Novartis is most often covered alongside Adalimumab, which appears in 1 of these 4 stories. The 35-day window averages about 0.8 stories each week.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in markets, which accounts for 3 of those 4, with the remainder spread across 1 other category. Novartis is most often covered alongside Adalimumab, which appears in 1 of these 4 stories. The 35-day window averages about 0.8 stories each week. Source depth averages 2.5 original sources per story, versus 2.6 across the same-window beat baseline. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. We currently track 4 Finance stories that mention Novartis, published between February 19, 2026 and March 25, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 2957 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Novartis. Shared-story counts are live from our verified record — not editorial picks.
Expected Rebalancing
Passive funds expected to complete divestment of RNAM shares to match new index weights.
Earnings Previews
Seeking Alpha releases Q4 2025 previews for both Voyager and Zevra.
CFO Appointment
Zevra Therapeutics names Justin Renz as Chief Financial Officer.
S&P Index Deletion
S&P Dow Jones Indices removes RNAM from Global BMI and TMI benchmarks.
Novartis Deal Closure
Avidity finalizes agreement with Novartis, launching Atrium Therapeutics spinout.
Voyager Partnership Update
Voyager reports progress on TRACER platform milestones with Novartis.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution and platform validation. Investors are focused on Zevra's Miplyffa launch trajectory and Voyager's CNS-focused partnership revenue.
Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices, effective March 2026. This technical deletion follows a major strategic milestone involving a deal closure with Novartis, signaling a period of significant structural transition for the biotech firm.
The Juvenile Idiopathic Arthritis (JIA) market is projected to expand at a 5.6% CAGR through 2036, reaching multi-billion dollar valuations driven by advanced biologic therapies. Major pharmaceutical players including Bristol-Myers Squibb and Novartis are positioned to capture significant share with next-generation treatments.
Novartis is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
